Dr Mark van Delft
Honorary (Fellow)
Department of Medical Biology (WEHI)
40 Scholarly works
0 Projects
HIGHLIGHTS
2025
Journal article
Re-appraising assays on permeabilized blood cancer cells testing venetoclax or other BH3 mimetic agents selectively targeting pro-survival BCL2 proteins
DOI: 10.1038/s41418-025-01487-72025
Journal article
Differential regulation of BAX and BAK apoptotic activity revealed by small molecules
DOI: 10.1126/sciadv.adr81462024
Journal article
Improved drug target deconvolution with PISA-DIA using an extended, overlapping temperature gradient
DOI: 10.1002/pmic.2023006442024
Journal article
Key residues in the VDAC2-BAK complex can be targeted to modulate apoptosis
DOI: 10.1371/journal.pbio.30026172023
Journal article
Depletion of the Mitochondrial E3 Ligase MARCH5 Induces Synthetic Lethality to BCL2 Inhibitor (Venetoclax) Therapy in Cell Lines Representative of Diverse Blood Cancers
DOI: 10.1182/blood-2023-1843922023
Journal article
The VEGFR/PDGFR tyrosine kinase inhibitor, ABT-869, blocks necroptosis by targeting RIPK1 kinase
DOI: 10.1042/BCJ202300352023
Journal article
Mitochondrial E3 ubiquitin ligase MARCHF5 controls BAK apoptotic activity independently of BH3-only proteins
DOI: 10.1038/s41418-022-01067-z
RECENT SCHOLARLY WORKS
2022
Journal article
The Lck inhibitor, AMG-47a, blocks necroptosis and implicates RIPK1 in signalling downstream of MLKL
DOI: 10.1038/s41419-022-04740-w2022
Book Chapter
The BCL-2 Family Proteins: Insights Into Their Mechanism of Action and Therapeutic Potential
DOI: 10.1016/B978-0-12-821618-7.00141-32021
Journal article
Too much death can kill you: inhibiting intrinsic apoptosis to treat disease
DOI: 10.15252/embj.2020107341